300,000 Shares in Boston Scientific Corporation $BSX Bought by Senator Investment Group LP

Senator Investment Group LP acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 300,000 shares of the medical equipment provider’s stock, valued at approximately $12,804,000.

A number of other institutional investors also recently bought and sold shares of the business. FWL Investment Management LLC acquired a new position in Boston Scientific in the 2nd quarter valued at about $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific during the 4th quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in Boston Scientific during the 4th quarter worth approximately $26,000. Sfam LLC purchased a new position in shares of Boston Scientific in the 4th quarter valued at approximately $29,000. Finally, Cresta Advisors Ltd. purchased a new position in shares of Boston Scientific in the 4th quarter valued at approximately $33,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently commented on BSX. Wolfe Research cut Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. The Goldman Sachs Group set a $71.00 price objective on shares of Boston Scientific in a research report on Thursday, May 28th. TD Cowen restated a “buy” rating and set a $56.00 price objective on shares of Boston Scientific in a research report on Tuesday, August 25th. Weiss Ratings cut shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, July 7th. Finally, Wells Fargo & Company lowered their target price on shares of Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating on the stock in a report on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Price Performance

BSX stock opened at $46.82 on Monday. The firm has a 50 day moving average of $46.56 and a 200-day moving average of $56.53. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The company has a market cap of $67.85 billion, a price-to-earnings ratio of 18.96, a PEG ratio of 1.02 and a beta of 0.56. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter last year, the business posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has authorized a stock repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Insiders Place Their Bets

In related news, Director Edward J. Ludwig purchased 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David C. Habiger purchased 2,100 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director directly owned 17,160 shares of the company’s stock, valued at $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 194,522 shares of company stock valued at $9,385,210 in the last ninety days. Insiders own 0.34% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.